Molecular Formula | C16H14N2 |
Molar Mass | 234.3 |
Density | 1.127±0.06 g/cm3(Predicted) |
Melting Point | 121 °C |
Boling Point | 398.3±37.0 °C(Predicted) |
Solubility | Chloroform (Slightly), Ethyl Acetate (Slightly) |
Appearance | White solid |
Color | Yellow |
pKa | 1.29±0.30(Predicted) |
Storage Condition | −20°C |
In vitro study | AG 1295 inhibits PDGFR autophosphorylation with IC 50 s of 0.3-0.5 μM and 0.5-1 μM for membrane autophosphorylation assays and Swiss 3T3 cells, respectively. AG1295 (10 μM, 100 μM) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro. Cell Viability Assay Cell Line: Rabbit conjunctival fibroblasts cells Concentration: 1 μM, 10 μM, 100 μM Incubation Time: 3 days Result: Inhibited rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB. |
In vivo study | AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibition of PDGFR-beta-triggered tyrosine phosphorylation. AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly reduces interstitial fibrosis as verified by a smaller Sirius-Red stained area and also by a reduced number of macrophages, and by the ED-A+ fibronectin deposition and the number of cells positive for alpha-smooth muscle actin. Animal Model: Sprague-Dawley rats (240-270 g) Dosage: 12 mg/kg Administration: Intraperitoneal injection; daily; for 14 or 21 days Result: Attenuated interstitial fibrosis in rat kidney after unilateral obstruction. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |